myNEO
myNEO Therapeutics is a biopharmaceutical company focused on developing novel immunotherapies for cancer. They utilize their ImmunoEngine platform to discover and target 'camyotopes', which are novel tumor targets found in the dark genome. These targets have the potential to improve immunotherapy response for a wider patient population. The company also offers services through myNEO Intelligence, which uses AI and a data-driven approach to assist biopharmaceutical companies in drug development, including target identification, candidate prioritization, and patient stratification. myNEO Therapeutics was founded in 2018 and has achieved milestones such as developing antigen prediction algorithms, discovering camyotopes, publishing scientific papers, securing intellectual property, and receiving awards.
myNEO
myNEO Therapeutics is a biopharmaceutical company focused on developing novel immunotherapies for cancer. They utilize their ImmunoEngine platform to discover and target 'camyotopes', which are novel tumor targets found in the dark genome. These targets have the potential to improve immunotherapy response for a wider patient population. The company also offers services through myNEO Intelligence, which uses AI and a data-driven approach to assist biopharmaceutical companies in drug development, including target identification, candidate prioritization, and patient stratification. myNEO Therapeutics was founded in 2018 and has achieved milestones such as developing antigen prediction algorithms, discovering camyotopes, publishing scientific papers, securing intellectual property, and receiving awards.